Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study. Giada Bianchi, MD, discusses tailoring therapy in myeloma, ...

Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...

Otero, MD, discusses findings from the LINKER-SMM1 trial presented at the IMS Annual Meeting. Paula Rodríguez-Otero, MD, consultant and deputy professor at the University of Navarra, Spain, discusses ...

Adding aglatimagene besadenovec (CAN-2409) to external beam radiation therapy (EBRT) was associated with greater lymphocyte infiltration of prostate tissue and greater lymphocyte- ...

Broader community enrollment improves external validity by capturing patients with comorbidities and real-world treatment patterns, while familiarizing clinicians with toxicity management before ...

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus ...

In an interview with Targeted OncologyTM, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with advanced ...

Those questions point to research that is still needed, Nieva says. This includes the role of deintensifying imaging and ...

Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...

Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...

Andrew Kuykendall, MD, discusses where rusfertide (Mimrylo) may fit within the treatment paradigm for polycythemia vera and ...

Out-of-pocket costs drove abandonment: fill rates fell from ~80% at ≤$15 to ~30% at $500–$2000, and to 21.6% when >$2000 commercially. Prior authorization dominated rejection reasons (32.1% Medicare; ...